Evaluation of hpv risk groups among women enrolled in the mulher cervical cancer screening study in Mozambique
Abstract Background Limited data are available about the distribution of human papillomavirus (HPV) among women undergoing cervical cancer screening in Mozambique. We describe the prevalence of high-risk HPV risk groups detected in women who participated in the MULHER Study, a prospective trial of M...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-04-01
|
| Series: | Infectious Agents and Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13027-025-00655-1 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850172989274849280 |
|---|---|
| author | Cristina Mendes de Oliveira Ricardina Rangeiro Nafissa Osman Ellen Baker Andrea Neves Arlete A. N. Mariano Guilhermina Tivir Joseph P. Thomas Jennifer Carns Viviane Andrade Carla Carrilho Eliane C. S. Monteiro Hannah Hoover Edson Chivambo Marcos Chissano Elizabeth Chiao Hira Atif Philip E. Castle Rebecca Richards-Kortum Eva Lathrop Kathleen M. Schmeler Cesaltina Lorenzoni Mila P. Salcedo |
| author_facet | Cristina Mendes de Oliveira Ricardina Rangeiro Nafissa Osman Ellen Baker Andrea Neves Arlete A. N. Mariano Guilhermina Tivir Joseph P. Thomas Jennifer Carns Viviane Andrade Carla Carrilho Eliane C. S. Monteiro Hannah Hoover Edson Chivambo Marcos Chissano Elizabeth Chiao Hira Atif Philip E. Castle Rebecca Richards-Kortum Eva Lathrop Kathleen M. Schmeler Cesaltina Lorenzoni Mila P. Salcedo |
| author_sort | Cristina Mendes de Oliveira |
| collection | DOAJ |
| description | Abstract Background Limited data are available about the distribution of human papillomavirus (HPV) among women undergoing cervical cancer screening in Mozambique. We describe the prevalence of high-risk HPV risk groups detected in women who participated in the MULHER Study, a prospective trial of Mozambican women undergoing cervical cancer screening with HPV testing. Methods From January 2020 to January 2023, 9,014 women aged 30–49 years in Maputo City and Gaza Province, Mozambique underwent cervical cancer screening. Cervicovaginal samples were self-collected (97.5%) or provider-collected (2.5%) and primary HPV testing was performed using the GeneXpert HPV testing platform (Cepheid Inc, USA) which provided data on HR-HPV risk groups: HPV16, HPV18/45 and 11 other HR-HPV types in aggregate. Women with a positive HR-HPV test underwent visual assessment using dilute acetic acid applied to the cervix for treatment decisions. Results Of the 9,014 women enrolled in the MULHER Study, 8,954 (99.3%) had a valid HPV test result. Of those, 2,805 (31.3%) tested positive for at least one HR-HPV group: HPV16 (n = 475, 16.9%), HPV18/45 (n = 686, 24.6%) and other HR-HPV (n = 2,150, 77.1%). A total of 17.8% were positive for multiple HPV HR groups. HR-HPV infection prevalence was higher among women living with HIV (WLWH) than HIV-negative women (39.7% vs. 24.3% respectively; p < 0.001). WLWH were more likely to test positive for HPV18/45 (p = 0.03) and for two or more HR-HPV risk groups (P < 0.0001) compared with HIV-negative women. HPV16 was the most frequently detected HR-HPV group (56.7%) among women diagnosed with invasive cervical cancer. Conclusions HR-HPV prevalence was high among Mozambican women aged 30–49 years, especially among WLWH, consistent with the high burden of cervical cancer in this population. HPV16 was the most common HR-HPV group among women with cervical cancer. Further study is needed to determine the role of HR-HPV genotyping in follow-up and treatment in Mozambique. |
| format | Article |
| id | doaj-art-82b615dd5bd548fa8a9162b415a4c8a4 |
| institution | OA Journals |
| issn | 1750-9378 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | BMC |
| record_format | Article |
| series | Infectious Agents and Cancer |
| spelling | doaj-art-82b615dd5bd548fa8a9162b415a4c8a42025-08-20T02:19:57ZengBMCInfectious Agents and Cancer1750-93782025-04-012011710.1186/s13027-025-00655-1Evaluation of hpv risk groups among women enrolled in the mulher cervical cancer screening study in MozambiqueCristina Mendes de Oliveira0Ricardina Rangeiro1Nafissa Osman2Ellen Baker3Andrea Neves4Arlete A. N. Mariano5Guilhermina Tivir6Joseph P. Thomas7Jennifer Carns8Viviane Andrade9Carla Carrilho10Eliane C. S. Monteiro11Hannah Hoover12Edson Chivambo13Marcos Chissano14Elizabeth Chiao15Hira Atif16Philip E. Castle17Rebecca Richards-Kortum18Eva Lathrop19Kathleen M. Schmeler20Cesaltina Lorenzoni21Mila P. Salcedo22DasaHospital Central de MaputoHospital Central de MaputoDepartment of Gynecologic Oncology & Reproductive Medicine, The University of Texas MD Anderson Cancer CenterHospital Geral e Centro de Saúde José MacamoHospital Geral e Centro de Saúde de MavalanePopulation Services InternationalDepartment of Oncology Care & Research, The University of Texas MD Anderson CancerRice UniversityICON plcHospital Central de MaputoHospital Geral e Centro de Saúde de MavalanePopulation Services InternationalPopulation Services InternationalPopulation Services InternationalDepartment of Epidemiology, The University of Texas MD Anderson Cancer CenterUniversidade Eduardo Mondlane (UEM)National Cancer InstituteRice UniversityPopulation Services InternationalDepartment of Gynecologic Oncology & Reproductive Medicine, The University of Texas MD Anderson Cancer CenterHospital Central de MaputoDepartment of Gynecologic Oncology & Reproductive Medicine, The University of Texas MD Anderson Cancer CenterAbstract Background Limited data are available about the distribution of human papillomavirus (HPV) among women undergoing cervical cancer screening in Mozambique. We describe the prevalence of high-risk HPV risk groups detected in women who participated in the MULHER Study, a prospective trial of Mozambican women undergoing cervical cancer screening with HPV testing. Methods From January 2020 to January 2023, 9,014 women aged 30–49 years in Maputo City and Gaza Province, Mozambique underwent cervical cancer screening. Cervicovaginal samples were self-collected (97.5%) or provider-collected (2.5%) and primary HPV testing was performed using the GeneXpert HPV testing platform (Cepheid Inc, USA) which provided data on HR-HPV risk groups: HPV16, HPV18/45 and 11 other HR-HPV types in aggregate. Women with a positive HR-HPV test underwent visual assessment using dilute acetic acid applied to the cervix for treatment decisions. Results Of the 9,014 women enrolled in the MULHER Study, 8,954 (99.3%) had a valid HPV test result. Of those, 2,805 (31.3%) tested positive for at least one HR-HPV group: HPV16 (n = 475, 16.9%), HPV18/45 (n = 686, 24.6%) and other HR-HPV (n = 2,150, 77.1%). A total of 17.8% were positive for multiple HPV HR groups. HR-HPV infection prevalence was higher among women living with HIV (WLWH) than HIV-negative women (39.7% vs. 24.3% respectively; p < 0.001). WLWH were more likely to test positive for HPV18/45 (p = 0.03) and for two or more HR-HPV risk groups (P < 0.0001) compared with HIV-negative women. HPV16 was the most frequently detected HR-HPV group (56.7%) among women diagnosed with invasive cervical cancer. Conclusions HR-HPV prevalence was high among Mozambican women aged 30–49 years, especially among WLWH, consistent with the high burden of cervical cancer in this population. HPV16 was the most common HR-HPV group among women with cervical cancer. Further study is needed to determine the role of HR-HPV genotyping in follow-up and treatment in Mozambique.https://doi.org/10.1186/s13027-025-00655-1HPVCervical cancerScreening |
| spellingShingle | Cristina Mendes de Oliveira Ricardina Rangeiro Nafissa Osman Ellen Baker Andrea Neves Arlete A. N. Mariano Guilhermina Tivir Joseph P. Thomas Jennifer Carns Viviane Andrade Carla Carrilho Eliane C. S. Monteiro Hannah Hoover Edson Chivambo Marcos Chissano Elizabeth Chiao Hira Atif Philip E. Castle Rebecca Richards-Kortum Eva Lathrop Kathleen M. Schmeler Cesaltina Lorenzoni Mila P. Salcedo Evaluation of hpv risk groups among women enrolled in the mulher cervical cancer screening study in Mozambique Infectious Agents and Cancer HPV Cervical cancer Screening |
| title | Evaluation of hpv risk groups among women enrolled in the mulher cervical cancer screening study in Mozambique |
| title_full | Evaluation of hpv risk groups among women enrolled in the mulher cervical cancer screening study in Mozambique |
| title_fullStr | Evaluation of hpv risk groups among women enrolled in the mulher cervical cancer screening study in Mozambique |
| title_full_unstemmed | Evaluation of hpv risk groups among women enrolled in the mulher cervical cancer screening study in Mozambique |
| title_short | Evaluation of hpv risk groups among women enrolled in the mulher cervical cancer screening study in Mozambique |
| title_sort | evaluation of hpv risk groups among women enrolled in the mulher cervical cancer screening study in mozambique |
| topic | HPV Cervical cancer Screening |
| url | https://doi.org/10.1186/s13027-025-00655-1 |
| work_keys_str_mv | AT cristinamendesdeoliveira evaluationofhpvriskgroupsamongwomenenrolledinthemulhercervicalcancerscreeningstudyinmozambique AT ricardinarangeiro evaluationofhpvriskgroupsamongwomenenrolledinthemulhercervicalcancerscreeningstudyinmozambique AT nafissaosman evaluationofhpvriskgroupsamongwomenenrolledinthemulhercervicalcancerscreeningstudyinmozambique AT ellenbaker evaluationofhpvriskgroupsamongwomenenrolledinthemulhercervicalcancerscreeningstudyinmozambique AT andreaneves evaluationofhpvriskgroupsamongwomenenrolledinthemulhercervicalcancerscreeningstudyinmozambique AT arleteanmariano evaluationofhpvriskgroupsamongwomenenrolledinthemulhercervicalcancerscreeningstudyinmozambique AT guilherminativir evaluationofhpvriskgroupsamongwomenenrolledinthemulhercervicalcancerscreeningstudyinmozambique AT josephpthomas evaluationofhpvriskgroupsamongwomenenrolledinthemulhercervicalcancerscreeningstudyinmozambique AT jennifercarns evaluationofhpvriskgroupsamongwomenenrolledinthemulhercervicalcancerscreeningstudyinmozambique AT vivianeandrade evaluationofhpvriskgroupsamongwomenenrolledinthemulhercervicalcancerscreeningstudyinmozambique AT carlacarrilho evaluationofhpvriskgroupsamongwomenenrolledinthemulhercervicalcancerscreeningstudyinmozambique AT elianecsmonteiro evaluationofhpvriskgroupsamongwomenenrolledinthemulhercervicalcancerscreeningstudyinmozambique AT hannahhoover evaluationofhpvriskgroupsamongwomenenrolledinthemulhercervicalcancerscreeningstudyinmozambique AT edsonchivambo evaluationofhpvriskgroupsamongwomenenrolledinthemulhercervicalcancerscreeningstudyinmozambique AT marcoschissano evaluationofhpvriskgroupsamongwomenenrolledinthemulhercervicalcancerscreeningstudyinmozambique AT elizabethchiao evaluationofhpvriskgroupsamongwomenenrolledinthemulhercervicalcancerscreeningstudyinmozambique AT hiraatif evaluationofhpvriskgroupsamongwomenenrolledinthemulhercervicalcancerscreeningstudyinmozambique AT philipecastle evaluationofhpvriskgroupsamongwomenenrolledinthemulhercervicalcancerscreeningstudyinmozambique AT rebeccarichardskortum evaluationofhpvriskgroupsamongwomenenrolledinthemulhercervicalcancerscreeningstudyinmozambique AT evalathrop evaluationofhpvriskgroupsamongwomenenrolledinthemulhercervicalcancerscreeningstudyinmozambique AT kathleenmschmeler evaluationofhpvriskgroupsamongwomenenrolledinthemulhercervicalcancerscreeningstudyinmozambique AT cesaltinalorenzoni evaluationofhpvriskgroupsamongwomenenrolledinthemulhercervicalcancerscreeningstudyinmozambique AT milapsalcedo evaluationofhpvriskgroupsamongwomenenrolledinthemulhercervicalcancerscreeningstudyinmozambique |